What is CANOC and how did the collaboration come about?
The human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) epidemic in Canada, as in the USA and other high-income countries, is concentrated in a number of groups. At the end of 2008, there were an estimated 65 000 HIV-positive individuals living in Canada, and 2300-4300 new infections occurring annually across the country.
1 Men who have sex with men (MSM) and injection drug users (IDUs) are the key affected population in this epidemic, and represent 48 and 17% of the population infected with HIV in 2008, respectively. Heterosexuals from endemic and non-endemic areas represent 14 and 17% of cases, respectively, and are another key group. Aboriginal (First Nations, Inuit and Métis) people are disproportionately represented and, despite accounting for only 3.8% of the Canadian population, accounted for 12.5% of HIV-positive tests in 2008. The number of women living with HIV in Canada also continues to grow, with 14 300 women living with HIV at the end of 2008, which is a 17% increase from the estimated 12 200 women living with HIV at the end of 2005. Three provinces, Ontario, Quebec and British Columbia (BC), carry the greatest burden of the epidemic and the majority of the people infected in these provinces live in the cities of Toronto, Montreal and Vancouver. 1 The delivery of antiretroviral therapy (ART) varies by province. Although health care is publicly funded in Canada, where medically necessary, hospital and physician services are universally provided, and medication coverage is provided through a combination of public and private mechanisms, which differ between provinces. Provincial and territorial programmes for HIV antiretroviral treatment supply and distribution range from complete coverage for all people living with HIV within a given province, to special coverage categories, or coverage through programmes with income-based deductibles. The largest programmes are in the provinces of Ontario, Québec, BC and Alberta. Combined, these programmes spent over $300 million on antiretroviral treatment in 2001-02. 2 The Canadian Observational Cohort (CANOC) collaboration is Canada's first interprovincial collaborative cohort of HIV-positive individuals on ART. There are currently nine adult clinical HIV cohorts from research centres, universities and clinics in BC, Ontario and Québec and one national prospective interval cohort (the Canadian Co-Infection Cohort Study) participating in CANOC (Table 1) . The initial collaboration focused on a representative group of cohorts serving the largest population centres in Canada but the collaboration is open to cohorts from other sites and provinces in the future. These nine cohorts encompass patients from all transmission categories and various models of care (from community-based clinics to tertiary care facilities).
CANOC is limited to persons who have initiated combination ART (cART), defined as the use of three or more antiretroviral drugs, on or after 1 January 2000 with no prior antiretroviral experience. We have focused on naive patients initiating cART, because this patient group was felt to be of most clinical interest for the evaluation of modern ART regimens in Canada. As of 31 March 2009, 4560 participants from these nine cohorts met the study inclusion criteria. CANOC represents $8% of the total HIV-positive population in Canada, one-quarter of all HIV-positive people in Canada who are currently on ART and approximately half of those who initiated cART since 2000. 4 This is the largest sample of HIV-positive people on ART compiled in Canada and represents one of the most representative samples in a high-income country.
What are the primary objectives?
The primary aims of CANOC are to develop a nationally and internationally recognized and policy relevant programme of research in HIV therapeutics and population and public health in Canada; to establish mentoring, training and research opportunities for graduate students, post-doctoral fellows and clinicians interested in HIV cohort research in Canada; and to improve research and dissemination to physicians and individuals living with HIV and to improve knowledge translation of research regarding HIV therapeutics into provincial, national and international HIV treatment guidelines. Examples of some research topics currently under investigation include: examining regional differences in viral load testing in Canada; 5 clinical and socio-demographic characteristics associated with time to virological suppression; 6 and clinical outcomes associated with CD4 cell count recovery among virologically suppressed individuals. 7 What are the recruitment and attrition rates?
Since CANOC is based on electronic submission of patients' clinical records from each cohort, patients are not individually recruited into the study. Patients will only be lost to follow-up from CANOC when they are lost to follow-up from individual cohorts. Currently, data for approximately 500 new naïve patients initiating cART therapy are submitted to CANOC each year. The median duration of follow-up is presently 36 months but is expected to increase with time. The loss to follow-up rate was 8.3% over the study period.
How are the data collected and managed?
Electronic data extraction of a pre-defined set of demographic, laboratory and clinical variables is performed at the data centres of the nine participating cohort studies and submitted annually to the BC Centre for Excellence in HIV/AIDS in Vancouver for pooling, data cleaning and analysis. Table 2 displays the structure of the standardized data collection; future data cuts will include a wider selection of data elements. All data are stripped of names and other personal identifiers prior to being sent to the Data Coordinating Site and a unique CANOC study number is assigned to each participant. Overlap between cohorts is identified within provinces before data are sent to the Data Coordinating Site. A data dictionary has been developed by the data analysts and is shared among the investigators. All data are managed in a central relational database and an audit trail has been created for all data changes. Access to CANOC electronic data at the Data Coordinating Site is password protected and limited to essential study personnel. All participating cohorts received research ethics board approval to contribute anonymous patient data to CANOC adhering to established standards in data sharing/linkage and data security/residual disclosure. In the case of the Ontario HIV Treatment Network (OHTN) Cohort Study (OCS), additional approval was received from the OCS Governance Committee to release Ontario data to participate in CANOC. Data submitted to the Data Coordinating Site in Vancouver are used only to address specific research questions approved by the CANOC Scientific Steering Committee and ownership of individual cohort data remains with the contributing cohort. Data elements used in any scientific publications are aggregated and do not identify individual study participants.
Baseline demographic and clinical characteristics of the CANOC participants are described in Table 3 .
Training opportunities
There have been limited opportunities in Canada for training graduate students, post-doctoral fellows, medical trainees and interested community members in the area of HIV cohort research. The team approach to training and knowledge translation creates unique opportunities for advanced multi-site and multiinvestigator training. A total of $100 000 per year will be offered for fellowships at Masters, PhD, postdoctoral and clinician scientist levels and will be awarded to the most qualified applicants at any level.
Applicants must submit a proposal for a CANOC research project and must be supervised by a CANOC investigator. Training awards are for a 1-year period but are renewable. Currently, CANOC is supporting two Masters and three doctoral students.
Knowledge translation and dissemination
Representatives of affected communities have been invited to sit on the team's Community Advisory 8 This information represents the committee's interpretation of research findings relating to current treatment of HIV/AIDS. Through such mechanisms, the cohort team has direct avenues for disseminating findings to interested health-care practitioners in their respective provinces. Relevant treatment-related results are also relayed to the appropriate therapeutic guideline committees across Canada, so that further decisions about whether these findings have any implications for current guidelines can be made.
CANOC encompasses a broad spectrum of expertise with individuals skilled in biomedical statistics, epidemiology, health services research, infectious diseases, population health, primary care, psychology, respiratory medicine and virology. Team members have demonstrated track records in publishing research findings in high-impact peer-reviewed scientific journals and presenting at academic conferences, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and will continue to pursue these avenues as a means of promoting knowledge translation. Although the team recognizes that publishing in academic journals alone is not sufficient to ensure knowledge translation, our experience is that adherence to the highest standard of peer review is still required to ensure widespread acceptance of research findings, in particular the more controversial studies that are common to our programme. Finally, our website (http://www.canoc.ca) is an important tool for communicating our findings to other research groups in Canada and worldwide. Plain language summaries of research findings will be posted on the website.
What has been found?
As noted above, a number of studies are being conducted and the results of these works have been presented at conferences in Canada and internationally. [5] [6] [7] Unique to this cohort collaboration is our ability to create individual community profiles for each participant based upon Canadian Census data. Participants that have a defined geographic location based on either their postal codes or census dissemination areas were linked to the 2006 Census at the dissemination area level. The variables of interest from the 2006 Census included median income, prevalence of low income, education, unemployment and aboriginal identity. Table 4 shows a comparison of CANOC participants and the general population, broken down by CANOC census catchment areas. Preliminary analyses demonstrate that people enrolled in CANOC generally have lower income and higher unemployment rates and are more likely to have finished high school than the general population. Eleven additional protocols/projects are currently underway.
What are the main strengths and weaknesses?
With nine cohorts, 4560 participants and 31 investigators with a broad spectrum of expertise, we have good representation of the HIV-positive individuals in Canada who initiated ART after January 2000 and strong commitment from the HIV research community in Canada. Although the initial combined data set was quite streamlined, the data set will be enhanced annually at each subsequent data cut by inclusion of more cohort members and a wider selection of data elements. Linkages with vital statistics and census tract databases will further enrich our dataset.
As with any cohort study, there are a number of inherent limitations with our study. Most notably, patients were not randomly assigned to ART or sampled, so may not be representative of the Canadian population infected with HIV/AIDS and on treatment. Patients who initiated therapy prior to January 2000 are not included in the cohort, so our findings will only be generalizable to individuals who have initiated therapy more recently. The cohorts involved in the collaboration are currently limited to three provinces (BC, Ontario, Quebec) of Canada. Although these provinces are representative of the largest HIV-positive populations in Canada, the collective cohort may not be fully representative of the HIV-infected population in Canada. Differences in clinical outcomes among cohorts may result due to by variations in the timing of follow-up visits and differential losses to follow-up between cohorts. Although there is a likely considerable heterogeneity between the cohorts, these differences are more of a strength than a weakness, since this heterogeneity will allow us to better understand how various factors work together to influence the health of HIV-infected individuals.
How can I collaborate? Principles of collaboration
We welcome Canadian cohorts that are not members of CANOC to join our collaboration. Our 'principles of collaboration' are based on those principles approved and active in the ART Cohort collaboration, 27 the North American AIDS Cohort Collaboration on Research and Design 28 and the Ontario HIV Treatment Network cohort. 29 The cohorts in the current collaboration were set up for various purposes and all existed prior to the development of CANOC. The majority are clinic-based populations, except in BC, where the study population is based on all 
Conclusions
Cohort collaborations provide the strongest level of evidence for research in areas such as disease progression, rare adverse events and rare exposures. Our present efforts of collaboration provide us with the largest amount of current Canadian patient information ever collected. Implementing successful research will require knowledge of patient-important clinical issues, population-level issues and issues likely to be of relevance to policy makers. The CANOC collaboration aims to put Canadian HIV/AIDS research on par with other international collaborations in the field. This will be achieved through the development of a nationally and internationally recognized and policy-relevant programme of research in HIV therapeutics and population and public health, and through the establishment of training and research opportunities for graduate students, post-doctoral fellows and clinicians across the country interested in HIV/AIDS cohort research. Our efforts to improve research dissemination to physicians and persons living with HIV as well as to improve knowledge translation of research on HIV/AIDS therapeutics into provincial, national and international HIV/AIDS treatment guidelines will contribute to global recognition of the CANOC collaboration.
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